

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

BRUCE E. KATZ, M.D., P.C. d/b/a Juva Skin
and Laser Center, a New York professional
corporation, individually and as the
representative of a class of similarly-situated
persons,

Plaintiff,

v.

FUSION PHARMACY, LLC, a Utah limited
liability company, and FUSION SPECIALTY
PHARMACY, INC., a Utah corporation,

Defendants.

CLASS ACTION COMPLAINT

Plaintiff, BRUCE E. KATZ, M.D., P.C. d/b/a Juva Skin and Laser Center (“Plaintiff”), brings this action on behalf of itself and all others similarly situated, through its attorneys, and except as to those allegations pertaining to Plaintiff or its attorneys, which allegations are based upon personal knowledge, alleges the following upon information and belief against Defendants, FUSION PHARMACY, LLC and FUSION SPECIALTIY PHARMACY, INC. (“Defendants”):

PRELIMINARY STATEMENT

1. This case challenges Defendants’ practice of sending unsolicited advertisements via facsimile.
2. The federal Telephone Consumer Protection Act of 1991, as amended by the Junk Fax Prevention Act of 2005, 47 U.S.C. § 227 (hereafter “TCPA” or the “Act”), and the regulations promulgated under the Act, prohibit a person or entity from sending fax advertisements without the recipient’s prior express invitation or permission. The TCPA provides a private right of action and provides statutory damages of \$500 per violation.

3. On or about January 17, 2020, Defendants sent Plaintiff an unsolicited fax advertisement in violation of the TCPA (the “Fax”), a true and correct copy of which is attached hereto as Exhibit A and made a part hereof. The Fax describes the commercial availability and/or quality of Defendants’ property, goods or services, namely, Defendants’ “GENERIC ACCUTANE® / ISOTRETINOIN,” and other pharmaceuticals. (Exhibit A).

4. Plaintiff alleges on information and belief that Defendants have sent, and continue to send, unsolicited advertisements via facsimile transmission in violation of the TCPA, including but not limited to the advertisement sent to Plaintiff.

5. Defendants’ unsolicited faxes have damaged Plaintiff and the class in that a junk fax recipient loses the use of its fax machine, paper, and ink toner. An unsolicited fax wastes the recipient’s valuable time that would have been spent on something else. A junk fax intrudes into the recipient’s seclusion and violates the recipient’s right to privacy. Unsolicited faxes occupy fax lines, prevent fax machines from receiving authorized faxes, prevent their use for authorized outgoing faxes, cause undue wear and tear on the recipients’ fax machines, and require additional labor to attempt to discern the source and purpose of the unsolicited message.

6. On behalf of itself and all others similarly situated, Plaintiff brings this case as a class action asserting claims against Defendants under the TCPA. Plaintiff seeks to certify a class which were sent the Fax and other unsolicited fax advertisements that were sent without prior express invitation or permission and without compliant opt-out language (to the extent the affirmative defense of “established business relationship” is alleged). Plaintiff seeks statutory damages for each violation of the TCPA and injunctive relief.

7. Plaintiff is informed and believes, and upon such information and belief avers, that this action is based upon a common nucleus of operative facts because the facsimile transmissions

at issue were and are being done in the same or similar manner. This action is based on the same legal theory, namely liability under the TCPA. This action seeks relief expressly authorized by the TCPA: (i) injunctive relief enjoining Defendants, their employees, agents, representatives, contractors, affiliates, and all persons and entities acting in concert with them, from sending unsolicited advertisements in violation of the TCPA; and (ii) an award of statutory damages in the minimum amount of \$500 for each violation of the TCPA, and to have such damages trebled, as provided by § 227(b)(3) of the Act in the event the Court determines any TCPA violations were willful or knowing.

JURISDICTION AND VENUE

8. This Court has subject matter jurisdiction under 28 U.S.C. § 1331 and 47 U.S.C. § 227.

9. This Court has personal jurisdiction over Defendants because Defendants transact business within this judicial district, have made contacts within this judicial district, and/or have committed tortious acts within this judicial district.

PARTIES

10. Plaintiff, BRUCE E. KATZ, M.D., P.C. d/b/a Juva Skin and Laser Center, is a New York professional corporation with its principal place of business within this judicial district.

11. Defendant, FUSION PHARMACY, LLC, is a Utah limited liability company, and Defendant, FUSION SPECIALTY PHARMACY, INC., is a Utah corporation. Defendants' principal place of business is in Santa Clara, Utah.

FACTS

12. On information and belief, Defendants are for-profit entities that are in the compounding pharmaceutical business and are licensed in 26 states.

13. On or about January 17, 2020, Defendants sent an unsolicited facsimile to Plaintiff using a telephone facsimile machine, computer, or other device. *See* Exhibit A. Plaintiff received the Fax on a stand-alone fax machine.

14. The first page of the Fax states in part the following:

**“ARE YOUR
PATIENTS PAYING
TOO MUCH FOR
GENERIC
AC CUTANE® /
ISOTRETINOLN?”**

The second page of the fax is a list of various indications, drugs to treat same, and pricing detail. The second page states in part:

FREE Standard Shipping included! Don’t see a formula you like? Call us and we can formulate it for you!

(*See* Ex. A).

15. Defendants’ website, FusionSpecialityPharmacy.com, (last visited 2/7/20) states:

Fusion Specialty Pharmacy is a compounding pharmacy in St. George, Utah dedicated to formulating creative, individualized, and compounded medications that can improve compliance, maximize the potential for therapeutic success, and reduce the overall cost of healthcare. One of our goals is to offer a personalized service to our patients and help them understand their core ailment. This will allow us to work closely with their physicians and create a customized formulation. Fusion Specialty Pharmacy offers the personalized attention that other pharmacies are unable to offer due to their business environment.

16. The Fax advertises the commercial availability and/or quality of Defendants' property, goods, or services, namely, their generic compounded pharmaceuticals. Therefore, the Fax is an advertisement under the TCPA and the regulations implementing the TCPA.

17. On information and belief, Defendants receive some or all of the revenues from, and profit and benefit from, the sales of their compounded pharmaceuticals advertised on Exhibit A.

18. Defendants created or made the Fax, or directed a third party to do so, and the Fax was sent by or on behalf of Defendants with Defendants' knowledge and authorization.

19. Plaintiff did not give Defendants "prior express invitation or permission" to send the Fax.

20. On information and belief, Defendants faxed to at least forty recipients the same and other unsolicited facsimile advertisements without prior express invitation or permission, and without the required opt-out language, thereby precluding Defendants from successfully invoking the affirmative defense of established business relationship.

21. There are no reasonable means for Plaintiff (or any other class member) to avoid receiving unauthorized faxes. Fax machines are left on and ready to receive the urgent communications their owners desire to receive.

22. Defendants' facsimile attached as Exhibit A does not display a compliant opt-out notice as required by 47 C.F.R. § 227(b)(1)(C) and 47 C.F.R. § 64.1200(a)(4).

CLASS ACTION ALLEGATIONS

23. In accordance with Fed. R. Civ. P. 23(b)(3), Plaintiff brings this class action pursuant to the TCPA, on behalf of the following class of persons:

All persons who (1) on or after four years prior to the filing of this action, (2) were sent telephone facsimile messages of material

advertising the commercial availability or quality of any property, goods, or services by or on behalf of Defendants, (3) from whom Defendants did not obtain “prior express invitation or permission” to send fax advertisements, or (4) with whom Defendants did not have an established business relationship, and (5) where the fax advertisements did not include an opt-out notice compliant with 47 C.F.R. § 64.1200(a)(4).

Excluded from the Class are Defendants, their employees and agents, and members of the Judiciary. Plaintiff seeks to certify a class that includes but is not limited to the fax advertisement(s) sent to Plaintiff. Plaintiff reserves the right to amend the class definition upon completion of class certification discovery.

24. Class Size (Fed. R. Civ. P. 23(a)(1)): Plaintiff is informed and believes, and upon such information and belief avers, that the number of persons and entities of the proposed Class is numerous and joinder of all members is impracticable. Plaintiff is informed and believes, and upon such information and belief avers, that the number of class members is at least forty.

25. Commonality (Fed. R. Civ. P. 23(a)(2)): Common questions of law and fact apply to the claims of all class members. Common material questions of fact and law include, but are not limited to, the following:

(a) Whether the Fax and other faxes sent during the class period constitute advertisements under the TCPA and its implementing regulations;

(b) Whether Defendants meet the definition of “sender” for direct TCPA liability, meaning a “person or entity on whose behalf a facsimile unsolicited advertisement is sent or whose goods or services are advertised or promoted in the unsolicited advertisement,” 47 C.F.R. § 64.1200(f)(10);

(c) Whether Defendants had prior express invitation or permission to send Plaintiff and the class fax advertisements;

(d) Whether the Fax contains an “opt-out notice” that complies with the requirements of § (b)(1)(C)(iii) of the Act, and the regulations promulgated thereunder, and the effect of the failure to comply with such requirements;

(e) Whether Defendants should be enjoined from faxing advertisements in the future;

(f) The manner and method Defendants used to compile or obtain the list of fax numbers to which it sent Exhibit A or other fax advertisements;

(g) Whether Defendants should be enjoined from sending fax advertisements in the future;

(h) Whether Plaintiff and the other members of the class are entitled to statutory damages; and

(i) Whether the Court should award treble damages.

26. Typicality (Fed. R. Civ. P. 23(a)(3)): Plaintiff's claims are typical of the claims of all class members. Plaintiff received the same or similar fax as the faxes sent by or on behalf of Defendants advertising the commercially availability and/or quality of property, goods or services of Defendants during the Class Period. Plaintiff is making the same claims and seeking the same relief for itself and all class members based upon the same federal statute. Defendants have acted in the same or in a similar manner with respect to Plaintiff and all the class members by sending Plaintiff and each member of the class the same or similar fax or faxes which did not contain compliant opt-out language or were sent without prior express invitation or permission.

27. Fair and Adequate Representation (Fed. R. Civ. P. 23(a)(4)): Plaintiff will fairly and adequately represent and protect the interests of the class. Plaintiff is interested in this matter, has no conflicts, and has retained experienced class counsel to represent the class.

28. Predominance and Superiority (Fed. R. Civ. P. 23(b)(3)): Common questions of law and fact predominate over any questions affecting only individual members, and a class action is superior to other methods for the fair and efficient adjudication of the controversy because:

(a) Proof of the claims of Plaintiff will also prove the claims of the class without the need for separate or individualized proceedings;

(b) Evidence regarding defenses or any exceptions to liability that Defendants may assert and attempt to prove will come from Defendants' records and will not require individualized or separate inquiries or proceedings;

(c) Defendants have acted and are continuing to act pursuant to common policies or practices in the same or similar manner with respect to all class members;

(d) The amount likely to be recovered by individual class members does not support individual litigation. A class action will permit a large number of relatively small claims involving virtually identical facts and legal issues to be resolved efficiently in one proceeding based upon common proofs; and

(e) This case is inherently manageable as a class action in that:

(i) Defendants identified persons to receive the fax transmissions and it is believed that Defendants' and/or Defendants' agents' computers and business records will enable Plaintiff to readily identify class members and establish liability and damages;

(ii) Liability and damages can be established for Plaintiff and the class with the same common proofs;

(iii) Statutory damages are provided for in the statute and are the same for all class members and can be calculated in the same or a similar manner;

(iv) A class action will result in an orderly and expeditious administration of claims and it will foster economics of time, effort and expense;

(v) A class action will contribute to uniformity of decisions concerning Defendants' practices; and

(vi) As a practical matter, the claims of the class are likely to go unaddressed absent class certification.

Claim for Relief for Violation of the TCPA, 47 U.S.C. § 227 *et seq.*

29. The TCPA makes it unlawful for any person to “use any telephone facsimile machine, computer or other device to send, to a telephone facsimile machine, an unsolicited advertisement” 47 U.S.C. § 227(b)(1)(C).

30. The TCPA defines “unsolicited advertisement” as “any material advertising the commercial availability or quality of any property, goods, or services which is transmitted to any person without that person's prior express invitation or permission, in writing or otherwise.” 47 U.S.C. § 227 (a) (5).

31. **Opt-Out Notice Requirements.** The TCPA strengthened the prohibitions against the sending of unsolicited advertisements by requiring, in section (b)(1)(C)(iii) of the Act, that senders of fax advertisements place a clear and conspicuous notice on the first page of the transmission that contains the following, among other things (hereinafter collectively the “Opt-Out Notice Requirements”):

A. a statement that the recipient is legally entitled to opt-out of receiving future faxed advertisements – knowing that he or she has the legal right to request an opt-out gives impetus for recipients to make such a request, if desired;

B. a statement that the sender must honor a recipient's opt-out request within 30 days and the sender's failure to do so is unlawful – thereby encouraging recipients to opt-out, if they did not want future faxes, by advising them that their opt-out requests will have legal “teeth”;

C. a statement advising the recipient that he or she may opt-out with respect to all of his or her facsimile telephone numbers and not just the ones that receive a faxed advertisement from the sender – thereby instructing a recipient on how to make a valid opt-out request for all of his or her fax machines; and

D. The opt-out language must be conspicuous.

The requirement of (1) above is incorporated from section (b)(D)(ii) of the Act. The requirement of (2) above is incorporated from section (b)(D)(ii) of the Act and the rules and regulations of the FCC in ¶ 31 of its 2006 Report and Order (*In re Rules & Regulations Implementing the Telephone Consumer Protection Act, Junk Prevention Act of 2005*, 21 F.C.C.R. 3787, 2006 WL 901720, which rules and regulations took effect on August 1, 2006). The requirements of (3) above are contained in section (b)(2)(E) of the Act and incorporated into the Opt-Out Notice Requirements via section (b)(2)(D)(ii). Compliance with the Opt-Out Notice Requirements is neither difficult nor costly. The Opt-Out Notice Requirements are important consumer protections bestowed by Congress upon consumers and businesses giving them the right, and means, to stop unwanted fax advertisements.

32. **2006 FCC Report and Order.** The TCPA, in section (b)(2) of the Act, directed the FCC to implement regulations regarding the TCPA, including the TCPA's Opt-Out Notice Requirements and the FCC did so in its 2006 Report and Order, which in addition provides among other things:

A. The definition of, and the requirements for, an established business relationship for purposes of the first of the three prongs of an exemption to liability under section (b)(1)(C)(i) of the Act and provides that the lack of an “established business relationship” precludes the ability to invoke the exemption contained in section (b)(1)(C) of the Act (*See* 2006 Report and Order ¶¶ 8-12 and 17-20);

B. The required means by which a recipient’s facsimile telephone number must be obtained for purposes of the second of the three prongs of the exemption under section (b)(1)(C)(ii) of the Act and provides that the failure to comply with these requirements precludes the ability to invoke the exemption contained in section (b)(1)(C) of the Act (*See* 2006 Report and Order ¶¶ 13-16);

C. The things that must be done in order to comply with the Opt-Out Notice Requirements for the purposes of the third of the three prongs of the exemption under section (b)(1)(C)(iii) of the Act and provides that the failure to comply with these requirements precludes the ability to invoke the exemption contained in section (b)(1)(C) of the Act (*See* 2006 Report and Order ¶¶ 24-34).

33. **The Fax.** Defendants sent the Fax on or about January 17, 2020, via facsimile transmission from a telephone facsimile machine, computer, or other device to the fax numbers and telephone facsimile machines of Plaintiff and members of the Class. The Fax constituted an advertisement under the Act and the regulations implementing the Act. Defendants failed to comply with the Opt-Out Notice Requirements in connection with the Fax. The Fax was transmitted to persons or entities without their prior express invitation or permission and/or Defendants are precluded from sustaining the established business relationship safe harbor with Plaintiff and other members of the class, because, *inter alia*, of the failure to comply with the Opt-

Out Notice Requirements. By virtue thereof, Defendants violated the TCPA and the regulations promulgated thereunder by sending the Fax via facsimile transmission to Plaintiff and members of the Class. Plaintiff seeks to certify a class which includes this Fax and all others sent during the four years prior to the filing of this case through the present.

34. **Defendants' Other Violations.** Plaintiff is informed and believes, and upon such information and belief avers, that during the period preceding four years of the filing of this Complaint and repeatedly thereafter, Defendants have sent via facsimile transmission from telephone facsimile machines, computers, or other devices to telephone facsimile machines faxes other than Exhibit A that constitute advertisements under the TCPA that were transmitted to persons or entities without their prior express invitation or permission (and/or that Defendants are precluded from sustaining the established business relationship safe harbor due to their failure to comply with the Opt-Out Notice Requirements). By virtue thereof, Defendants violated the TCPA and the regulations promulgated thereunder. Plaintiff is informed and believes, and upon such information and belief avers, that Defendants may be continuing to send unsolicited advertisements via facsimile transmission in violation of the TCPA and the regulations promulgated thereunder, and absent intervention by this Court, will do so in the future.

35. The TCPA provides a private right of action to bring this action on behalf of Plaintiff and Plaintiff Class to redress Defendants' violations of the Act, and provides for statutory damages. 47 U.S.C. § 227(b)(3). The Act also provides that injunctive relief is appropriate. *Id.*

36. The TCPA is a strict liability statute, so Defendants are liable to Plaintiff and the other class members even if its actions were only negligent.

37. Defendants knew or should have known that (a) Plaintiff and the other class members had not given prior express invitation or permission for Defendants or anybody else to

fax advertisements about the availability or quality of Defendants' property, goods, or services to be bought or sold; (b) Plaintiff and the other class members did not have an established business relationship; (c) Defendants transmitted advertisements; and (d) the Faxes did not contain the required Opt-Out Notice.

38. Defendants' actions caused injury to Plaintiff and the other class members. Receiving Defendants' junk faxes caused Plaintiff and other recipients to lose paper and toner consumed in the printing of Defendants' faxes. Defendants' faxes occupied Plaintiff's and class members' telephone lines and fax machines. Defendants' faxes cost Plaintiff and class members' time, as Plaintiff and its employees, as well as other class members and their employees, wasted their time receiving, reviewing, and routing Defendants' unauthorized faxes. That time otherwise would have been spent on Plaintiff's and the class members' business or personal activities. Defendants' faxes intruded into Plaintiff's and other class members' seclusion and violated their right to privacy, including their interests in being left alone. Finally, the injury and property damage sustained by Plaintiff and the other class members from the sending of Defendants' advertisements occurred outside of Defendants' premises.

WHEREFORE, Plaintiff, BRUCE E. KATZ, M.D., P.C. d/b/a Juva Skin and Laser Center, individually and on behalf of all others similarly situated, demands judgment in its favor and against Defendants, FUSION PHARMACY, LLC and FUSION SPECIALTY PHARMACY, INC., jointly and severally, as follows:

A. That the Court adjudge and decree that the present case may be properly maintained as a class action, appoint Plaintiff as the representative of the class, and appoint Plaintiff's counsel as counsel for the class;

B. That the Court award actual monetary loss from such violations or the sum of five hundred dollars (\$500.00) for each violation, whichever is greater, and that the Court award treble damages of \$1,500.00 if the violations are deemed “willful or knowing”;

C. That the Court enjoin Defendants from additional violations; and

D. That the Court award pre-judgment interest, costs, and such further relief as the Court may deem just and proper.

Respectfully submitted,

BRUCE E. KATZ M.D., P.C. d/b/a Juva Skin and
Laser Center, individually and as the representative
of a class of similarly-situated persons,

By: /s/ Aytan Y. Bellin

Aytan Y. Bellin

BELLIN & ASSOCIATES LLC
50 Main Street, Suite 1000
White Plains, NY 10606
Telephone: (914) 358-5345
Facsimile: (212) 571-0284
Aytan.Bellin@bellinlaw.com

And

Ryan M. Kelly (*pro hac vice to be submitted*)

ANDERSON + WANCA

3701 Algonquin Road, Suite 500

Rolling Meadows, IL 60008

Telephone: 847-368-1500

rkelly@andersonwanca.com

EXHIBIT A

17-Jan-2020 17:22 UTC To: (12124219502)

**ARE YOUR
PATIENTS PAYING
TOO MUCH FOR
GENERIC
ACCUTANE® /
ISOTRETINOIN?**



Nationally Accredited Compounding Pharmacy | Licensed and Shipping to 26 States.

If you no longer wish to receive faxes from Fusion Specialty Pharmacy, please call 888-963-9923 or send a fax to 435-703-9681. We must process your request within 30 days.



1100 Canyon View Drive, Suite C, Santa Clara, UT 84765
 Phone: (888) 963-9923 | Fax: (855) 853-3465
 Email: rx@rx-fusion.com | Web: FusionSpecialtyPharmacy.com
 Social: @FusionSpecialtyPharmacy | #FusionIsBetterMedicine

FREE Standard Shipping included! Don't see a formula you like? Call us and we can formulate it for you!

Indication	Drug Name	Price
Acne	Benzoyl Peroxide/Clindamycin 5/1% in TruLipids® Lotion - 50g	\$ 76.98
	Benzoyl Peroxide/Clindamycin 5/1% OR 5/1% Cream - 50g	\$ 65.98
	Clindamycin/Tretinoin Gel 1/0.025% Cream in TruLipids® Lotion - 50g	\$ 76.98
	Erythromycin 2% Ointment - 30g	\$ 54.98
	Isotretinoin 10/20/40mg - 30ct	\$ 95.00
	Isotretinoin 30mg - 30ct	\$ 170.00
	Sulfacetamide/Precipitated Sulfur 10/1% Cream - 30g	\$ 43.98
	Tretinoin in Emollient OR Biopeptide 0.05 - 0.50% Cream - 30g (Biopeptide adds \$11)	\$ 65.98
Artificial Keratosis	Fluorouracil (Propylene Glycol/Vial) 1.25% Solution - 40ml	\$ 87.98
	Fluorouracil 1 - 4% Cream - 30g	\$ 54.98
Anesthetic	Benzocaine/Lidocaine/Tetracaine 20/5/4% Cream - 30g	\$ 54.98
Anti-Aging	Fluorinolone/Hydroquinone/Tretinoin (Tri-lite) 0.01/4/0.05% Cream - 30g	\$ 76.98
	Hydrocortisone/Hydroquinone/Sage Acid/Tretinoin 0.5/6/3/0.05% Cream (Platinum Plus) - 30g	\$ 71.48
Antifungal	Fluconazole in Recura™ 10% Cream - 15g	\$ 71.48
	Fluconazole/Miconazole in Recura™ 1/5% Cream - 15g	\$ 71.48
	Itraconazole in Recura™ 5% Cream - 10g	\$ 87.98
	Itraconazole/Diclofenac in DMSO 1/2% Solution - 10ml	\$ 43.98
	Itraconazole/Terbinafine/Fluconazole 1/1/3% Solution - 10ml	\$ 43.98
Burns	Lidocaine 2% with Aloe Vera in Pracasil® Plus Gel - 15g	\$ 55.00
Eczema	Clobetasol/Cyanocobalamin/Zinc 0.05/0.07/0.2% Cream - 60g	\$ 65.98
	Cyanocobalamin/Naltrexone 0.07/0.5% Cream - 60g	\$ 87.98
Hair Loss	Minoxidil 8.5%/Finasteride 0.1% Scalp Solution - 30ml	\$ 49.48
Pruritus	Lidocaine/Menthol/Triamcinolone 5/0.25/0.1% Cream - 120g	\$ 60.48
Rosacea	Azelaic Acid in Biopeptide 20% Cream - 30g	\$ 76.98
	Metronidazole/Niacinamide 1/4% Cream - 15g	\$ 43.98
Scar	Diphenhydramine/Hydrocortisone/Pentoxifylline/Prilocaine 2/3/0.5/3% Gel - 30g	\$ 99.00
Contracture	Pracasil® Plus Gel - 30g	\$ 65.98
	Pentoxifylline 1% Gel with t-GCg Gel - 30g	\$ 99.00
Hyperpigmented	Ascorbic Acid/Evocetuzine/Niacinamide/Trexamic Acid/Tretinoin 1/2/2/2/0.025% Gel - 30g	\$ 99.00
Hypertrophic	Ascorbic Acid/EGCg 2/1% Gel - 30g	\$ 99.00
Acne	Ascorbic Acid/Glycolic Acid/Lactic Acid/Niacinamide/Tretinoin 1/2.5/2.5/4/0.05% Gel - 30g	\$ 99.00
Stretch Marks	Collagen Hydrolysate/Glycolic Acid/Pentoxifylline/Tretinoin 0.3/1/0.1/0.5/0.01% Gel - 30g	\$ 99.00
Shingles	Acyclovir/Amiripityline/Diclofenac/Gabapentin/Naltrexone/Tetracaine 2/2/3/5/0.5/1% Gel - 60g	\$ 108.90
Wart	Bupivacaine/Carbetidine/Deoxy-d glucose/Diclofenac/Salicylic Acid/Urea 1/5/0.3/3/20/10% Cream (Wart 4) - 30g	\$ 65.98
	Fluorouracil/Salicylic Acid 2/12% Cream - 30g	\$ 76.98
	Pyruvic Acid 70% Liquid (Wart 5) - 30ml	\$ 71.48

If you no longer wish to receive faxes from Fusion Specialty Pharmacy, please call 888-963-9923 or send a fax to 435-703-9681. We must process your request within 30 days.